P1,P4-Bis(5'-uridyl) tetraphosphate (BioDeep_00000006088)

 

Secondary id: BioDeep_00001868588

human metabolite Endogenous


代谢物信息卡片


{[(2R,3S,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({[({[({[(2R,3S,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]oxy})phosphinic acid

化学式: C18H26N4O23P4 (789.9938)
中文名称: 地夸磷索
谱图信息: 最多检出来源 Homo sapiens(otcml) 47.06%

分子结构信息

SMILES: C1=CN(C(=O)NC1=O)C2C(C(C(O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OCC3C(C(C(O3)N4C=CC(=O)NC4=O)O)O)O)O
InChI: InChI=1S/C18H26N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1

描述信息

P1,P4-Bis(5-uridyl) tetraphosphate is involved in pyrimidine metabolism. It is a precurser for UTP. UTP is produced from P1,P4-Bis(5-uridyl) tetraphosphate by the action of bis(5-nucleosidyl)-tetraphosphatase [EC:3.6.1.17]. [HMDB]
P1,P4-Bis(5-uridyl) tetraphosphate is involved in pyrimidine metabolism. It is a precurser for UTP. UTP is produced from P1,P4-Bis(5-uridyl) tetraphosphate by the action of bis(5-nucleosidyl)-tetraphosphatase [EC:3.6.1.17].
C78283 - Agent Affecting Organs of Special Senses

同义名列表

11 个代谢物同义名

{[(2R,3S,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({[({[({[(2R,3S,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]oxy})phosphinic acid; P1,P4-Bis(5-uridyl) tetrahydrogen tetraphosphoric acid; P1,P4-Bis(5-uridyl) tetrahydrogen tetraphosphate; p(1),p(4)-Bis(uridin-5-yl) tetraphosphoric acid; P1,P4-Bis(5-uridyl) tetraphosphoric acid; P1,P4-Bis(5-uridyl) tetraphosphate; SCHEMBL19685428; Diquafosol; INS 365; INS-365; UppppU



数据库引用编号

15 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

1 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(1)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 5 ANXA5, EIF2AK3, MAPK4, MUC1, SOD1
Peripheral membrane protein 1 ANXA5
Endoplasmic reticulum membrane 2 CD4, EIF2AK3
Nucleus 5 EIF2AK3, KRT13, MAPK4, MUC1, SOD1
cytosol 5 ANXA5, EIF2AK3, KRT13, MAPK4, SOD1
nucleoplasm 2 MAPK4, SOD1
Cell membrane 7 CD4, MUC1, P2RY12, P2RY2, P2RY4, P2RY6, TNF
Multi-pass membrane protein 4 P2RY12, P2RY2, P2RY4, P2RY6
cell surface 2 P2RY12, TNF
glutamatergic synapse 1 P2RY4
neuronal cell body 2 SOD1, TNF
sarcolemma 1 ANXA5
plasma membrane 9 CD4, IFNLR1, MUC1, MUC5AC, P2RY12, P2RY2, P2RY4, P2RY6, TNF
Membrane 5 ANXA5, EIF2AK3, IFNLR1, MUC1, P2RY12
apical plasma membrane 3 MUC1, P2RY4, P2RY6
basolateral plasma membrane 2 P2RY4, P2RY6
extracellular exosome 7 ANXA5, KRT13, LYZ, MMP9, MUC1, MUC5AC, SOD1
endoplasmic reticulum 1 EIF2AK3
extracellular space 8 IL6, LCN1, LYZ, MMP9, MUC1, MUC5AC, SOD1, TNF
perinuclear region of cytoplasm 1 EIF2AK3
mitochondrion 1 SOD1
protein-containing complex 1 SOD1
Single-pass type I membrane protein 4 CD4, EIF2AK3, IFNLR1, MUC1
Secreted 3 IL6, MATN3, MUC5AC
extracellular region 9 ANXA5, IL6, LCN1, LYZ, MATN3, MMP9, MUC5AC, SOD1, TNF
mitochondrial matrix 1 SOD1
external side of plasma membrane 3 ANXA5, CD4, TNF
Secreted, extracellular space, extracellular matrix 1 MMP9
cytoplasmic vesicle 1 SOD1
axon cytoplasm 1 SOD1
Early endosome 1 CD4
recycling endosome 1 TNF
Single-pass type II membrane protein 1 TNF
vesicle 1 MUC1
presynaptic active zone membrane 1 P2RY4
Apical cell membrane 1 MUC1
Membrane raft 2 CD4, TNF
focal adhesion 1 ANXA5
extracellular matrix 2 MATN3, MUC5AC
Peroxisome 1 SOD1
mitochondrial intermembrane space 1 SOD1
collagen-containing extracellular matrix 3 ANXA5, MATN3, MMP9
intermediate filament 1 KRT13
dendrite cytoplasm 1 SOD1
Zymogen granule membrane 1 ANXA5
chromatin 1 MUC1
phagocytic cup 1 TNF
cytoskeleton 1 KRT13
intermediate filament cytoskeleton 1 KRT13
ficolin-1-rich granule lumen 1 MMP9
Golgi lumen 2 MUC1, MUC5AC
endoplasmic reticulum lumen 3 CD4, IL6, MATN3
matrilin complex 1 MATN3
specific granule lumen 1 LYZ
tertiary granule lumen 2 LYZ, MMP9
azurophil granule lumen 1 LYZ
vesicle membrane 1 ANXA5
clathrin-coated endocytic vesicle membrane 1 CD4
keratin filament 1 KRT13
mucus layer 1 MUC5AC
[Tumor necrosis factor, soluble form]: Secreted 1 TNF
T cell receptor complex 1 CD4
interleukin-6 receptor complex 1 IL6
endothelial microparticle 1 ANXA5
cell body membrane 1 P2RY12
cell projection membrane 1 P2RY12
interleukin-28 receptor complex 1 IFNLR1
[C-domain 2]: Secreted 1 TNF
[Tumor necrosis factor, membrane form]: Membrane 1 TNF
[C-domain 1]: Secreted 1 TNF


文献列表

  • Jiayan Chen, Yimeng Chen, Guanghao Qin, Liangzhe Li, Mingze Li, Yuan Cheng, Shuting Zhuang, Zhihui Li, Qing Zhang, Yi Wu, Lanting Yang, Salissou Moutari, Jonathan E Moore, Ling Xu, Wei He, Sile Yu, Emmanuel Eric Pazo, Xingru He. A protocol for a single center, randomized, controlled trial comparing the clinical efficacy of 3\% diquafosol and 0.1\% hyaluronic acid in diabetic patients with dry eye disease. Trials. 2023 Dec; 24(1):803. doi: 10.1186/s13063-023-07818-8. [PMID: 38087329]
  • Jiayan Chen, Guanghao Qin, Liangzhe Li, Yifan Qi, Huixin Che, He Huang, Yang Xia, Qing Zhang, Yi Wu, Lanting Yang, Salissou Moutari, Jonathan E Moore, Ling Xu, Wei He, Sile Yu, Emmanuel Eric Pazo, Xingru He. Protocol for a parallel assignment prospective, randomised, comparative trial to evaluate the safety and efficacy of intense pulsed light (IPL) combined with 3\% diquafosol (DQS) ophthalmic solution in dry eye syndrome. BMJ open. 2023 Aug; 13(8):e073055. doi: 10.1136/bmjopen-2023-073055. [PMID: 37643847]
  • Qian Liu, Wenjun Cheng, Changgeng Liu, Xin Jin, Shuai Ming, Duo Zhao, Xiaomei Feng. Evaluation of effects of 3\% diquafosol ophthalmic solution on preocular tear film stability after trabeculectomy. International ophthalmology. 2022 Nov; ?(?):. doi: 10.1007/s10792-022-02589-8. [PMID: 36414850]
  • Qing Zhang, Hongda Zhang, Guanghao Qin, Yi Wu, Yilin Song, Lanting Yang, Sile Yu, Xingru He, Jonathan E Moore, Salissou Moutari, Christoph Palme, Ling Xu, Wei He, Emmanuel Eric Pazo. Impact of Diquafosol Ophthalmic Solution on Tear Film and Dry Eye Symptom in Type 2 Diabetic Dry Eye: A Pilot Study. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2022 Mar; 38(2):133-140. doi: 10.1089/jop.2021.0083. [PMID: 35049373]
  • Lan Li, Rujun Jin, Ying Li, Hee Su Yoon, Hyeon Jeong Yoon, Kyung Chul Yoon. Effects of eye drops containing a mixture of 3\% diquafosol sodium and tocopherol acetate (vitamin E) on the ocular surface of murine dry eye. Cutaneous and ocular toxicology. 2021 Dec; 40(4):350-358. doi: 10.1080/15569527.2021.1973022. [PMID: 34496685]
  • Sangyoon Kim, Jonghoon Shin, Ji Eun Lee. A randomised, prospective study of the effects of 3\% diquafosol on ocular surface following cataract surgery. Scientific reports. 2021 04; 11(1):9124. doi: 10.1038/s41598-021-88589-7. [PMID: 33907267]
  • Ken-Ichi Endo, Asuka Sakamoto, Koushi Fujisawa. Diquafosol tetrasodium elicits total cholesterol release from rabbit meibomian gland cells via P2Y2 purinergic receptor signalling. Scientific reports. 2021 03; 11(1):6989. doi: 10.1038/s41598-021-86433-6. [PMID: 33772064]
  • Shima Fukuoka, Reiko Arita. Tear film lipid layer increase after diquafosol instillation in dry eye patients with meibomian gland dysfunction: a randomized clinical study. Scientific reports. 2019 06; 9(1):9091. doi: 10.1038/s41598-019-45475-7. [PMID: 31235821]
  • Xiangzhe Li, Boram Kang, Youngsub Eom, Hyung Keun Lee, Hyo Myung Kim, Jong Suk Song. The Protective Effect of a Topical Mucin Secretagogue on Ocular Surface Damage Induced by Airborne Carbon Black Exposure. Investigative ophthalmology & visual science. 2019 01; 60(1):255-264. doi: 10.1167/iovs.18-25964. [PMID: 30649152]
  • Norihiko Yokoi, Georgi As Georgiev. Tear Film-Oriented Diagnosis and Tear Film-Oriented Therapy for Dry Eye Based on Tear Film Dynamics. Investigative ophthalmology & visual science. 2018 11; 59(14):DES13-DES22. doi: 10.1167/iovs.17-23700. [PMID: 30481801]
  • Keisuke Ikeda, Cem Simsek, Takashi Kojima, Kazunari Higa, Motoko Kawashima, Murat Dogru, Takahiko Shimizu, Kazuo Tsubota, Jun Shimazaki. The effects of 3\% diquafosol sodium eye drop application on meibomian gland and ocular surface alterations in the Cu, Zn-superoxide dismutase-1 (Sod1) knockout mice. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2018 Apr; 256(4):739-750. doi: 10.1007/s00417-018-3932-x. [PMID: 29484560]
  • Shima Fukuoka, Reiko Arita. Increase in tear film lipid layer thickness after instillation of 3\% diquafosol ophthalmic solution in healthy human eyes. The ocular surface. 2017 10; 15(4):730-735. doi: 10.1016/j.jtos.2017.03.005. [PMID: 28363586]
  • Yung Hui Kim, Yeon Soo Kang, Hyo Seok Lee, Won Choi, In Cheon You, Kyung Chul Yoon. Effectiveness of Combined Tear Film Therapy in Patients with Evaporative Dry Eye with Short Tear Film Breakup Time. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2017 10; 33(8):635-643. doi: 10.1089/jop.2017.0019. [PMID: 28846481]
  • Yukihiro Matsumoto, Yuichi Ohashi, Hitoshi Watanabe, Kazuo Tsubota. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmology. 2012 Oct; 119(10):1954-60. doi: 10.1016/j.ophtha.2012.04.010. [PMID: 22739038]
  • Andrei A Ivanov, Hyojin Ko, Liesbet Cosyn, Savitri Maddileti, Pedro Besada, Ingrid Fricks, Stefano Costanzi, T Kendall Harden, Serge Van Calenbergh, Kenneth A Jacobson. Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2'-amino-2'-deoxy-2-thiouridine 5'-triphosphate. Journal of medicinal chemistry. 2007 Mar; 50(6):1166-76. doi: 10.1021/jm060903o. [PMID: 17302398]
  • Michael Samarkos, Haralampos M Moutsopoulos. Recent advances in the management of ocular complications of Sjögren's syndrome. Current allergy and asthma reports. 2005 Jul; 5(4):327-32. doi: 10.1007/s11882-005-0077-x. [PMID: 15967078]
  • J R Sabater, Y M Mao, C Shaffer, M K James, T G O'Riordan, W M Abraham. Aerosolization of P2Y(2)-receptor agonists enhances mucociliary clearance in sheep. Journal of applied physiology (Bethesda, Md. : 1985). 1999 Dec; 87(6):2191-6. doi: 10.1152/jappl.1999.87.6.2191. [PMID: 10601167]
  • C Teasdale, A M Mander, R Fifield, J W Keyser, R G Newcombe, L E Hughes. Serum beta2-microglobulin in controls and cancer patients. Clinica chimica acta; international journal of clinical chemistry. 1977 Jul; 78(1):135-43. doi: 10.1016/0009-8981(77)90346-1. [PMID: 69507]